You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6mg) or placebo for sleep disturbance and depressed mood

Serfaty, Marc Antonya c; Osborne, Debbiea; Buszewicz, Marta J.b; Blizard, Roberta; Raven, Peter W.a

International Clinical Psychopharmacology:
doi: 10.1097/YIC.0b013e32832c260b
Original Articles
Abstract

Sleep disturbance is common in major depressive disorder (MDD), and is often characterized by early-morning waking. Melatonin is a hypnotic and synchronizes circadian rhythms. It may also be an antidepressant. The melatonin agonists, ramelteon and agomelatine, have hypnotic and antidepressant properties, but there is a dearth of trials investigating the use of melatonin in MDD. This randomized, controlled trial aimed to determine whether exogenous melatonin is a sleep promoter and antidepressant. Thirty-three participants with a Diagnostic and Statistical Manual of Mental Disorders (fourth edition) diagnosis of MDD and early-morning waking were selected for a 4-week, randomized, double-blind trial of slow-release melatonin (6 mg; vs. placebo) given at bedtime over 4 weeks. Sleep was measured subjectively using sleep diaries and the Leeds Sleep Evaluation Questionnaire and objectively using wrist actigraphy. Of the 33 participants, 31 completed the trial. General Linear Modelling showed significant improvements in depression and sleep over time, but this was not specific to melatonin. However, there was a trend towards an improvement in mood with melatonin, and no adverse side effects were observed. In conclusion, melatonin may be beneficial for treating MDD, it seems to be safe and well tolerated, but its potential for treating depression in people who do not wish to take antidepressants requires further evaluation.

Author Information

aResearch Department of Mental Health Sciences (Royal Free Campus), UCL Medical School

bResearch Department of Primary Care and Population Health (Whittington Campus), University College Medical School

cThe Priory Hospital North London, London, UK

Correspondence to Dr Marc Antony Serfaty, BSc (Hons), MBChB, MRCPsych, MPhil, MD, Research Department of Mental Health Sciences (Royal Free Campus), University College Medical School, Rowland Hill Street, London NW3 2PF, UK

Tel: +44 20 7794 0500; fax: +44 20 7830 2808;

e-mail: m.serfaty@medsch.ucl.ac.uk

Preliminary results of this study were presented at a virtual meeting of the Society for Light Treatment and Biological Rhythms (Serfaty et al., 2003).

Received 30 May 2008 Accepted 26 March 2009

© 2010 Lippincott Williams & Wilkins, Inc.